The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM).
Ulrik Niels Lassen
No relevant relationships to disclose
Oliver L. Chinot
Consultant or Advisory Role - Roche
Honoraria - AstraZeneca; MSD; Roche
Research Funding - Merck; Roche
Catherine McBain
No relevant relationships to disclose
Morten Sorensen
Other Remuneration - Roche
Vibeke Andree Larsen
No relevant relationships to disclose
Maryline Barrie
No relevant relationships to disclose
Patrick Roth
Consultant or Advisory Role - MSD; Roche
Oliver Krieter
Employment or Leadership Position - Roche
Stock Ownership - Roche
Karen Wang
Employment or Leadership Position - Roche
Kai Habben
Employment or Leadership Position - Roche
Jean Tessier
Employment or Leadership Position - Roche
Angelika Lahr
Employment or Leadership Position - Roche
Matt Whiley
Employment or Leadership Position - Roche
Stock Ownership - Roche
Michael Weller
Consultant or Advisory Role - Antisense Pharma; Merck; Roche